|
Characteristic
|
All
|
Inoperable
|
Operable
|
|---|
|
No. of patients
|
55
|
21
|
34
|
|
Age (y), median (range)
|
71 (48–88)
|
81 (65–88)
|
70 (48–79)
|
|
Sex
|
|
Male
|
32 (58%)
|
15 (71%)
|
17 (50%)
|
|
Female
|
23 (42%)
|
6 (29%)
|
17 (50%)
|
|
Histology
|
|
Adenocarcinoma
|
44 (80%)
|
13 (62%)
|
31 (91%)
|
|
Squamous cell carcinoma
|
10 (18%)
|
8 (38%)
|
2 (6%)
|
|
NSCLC
|
1 (2%)
|
0 (0%)
|
1 (3%)
|
|
ECOG performance status
|
|
0
|
46 (84%)
|
12 (57%)
|
34 (100%)
|
|
1
|
7 (13%)
|
7 (33%)
|
0 (0%)
|
|
2
|
2 (4%)
|
2 (10%)
|
0 (0%)
|
|
Clinical stage (UICC 7th)
|
|
Stage IA
|
33 (60%)
|
13 (62%)
|
20 (59%)
|
|
Stage IB
|
22 (40%)
|
8 (38%)
|
14 (41%)
|
|
Longest tumor diameter (mm), median (range)
|
27 (10–50)
|
27 (14–46)
|
27 (10–50)
|
|
Tumor location
|
|
Center (72.6 Gy(RBE)/22 Fr)
|
6 (11%)
|
5 (24%)
|
1 (3%)
|
|
Periphery (66 Gy(RBE)/10 Fr)
|
49 (89%)
|
16 (76%)
|
33 (97%)
|
|
Tumor site
|
|
Upper and middle lobe
|
41 (75%)
|
16 (76%)
|
25 (74%)
|
|
Lower lobe
|
14 (25%)
|
5 (24%)
|
9 (26%)
|
|
Smoking
|
|
Yes
|
23 (42%)
|
12 (57%)
|
11 (32%)
|
|
No
|
32 (58%)
|
9 (43%)
|
23 (68%)
|
- Abbreviations, NSCLC unclassified non-small cell lung cancer, ECOG Eastern Cooperative Oncology Group; UICC 7th, Union for International Cancer Control 7th edition, Gy(RBE) grays relative effectiveness, Fr fraction
